Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Corrigendum: Dose reduction of...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Bibliographic Details
Main Authors: C. A. M. van Riel, C. A. J. Michielsens, M. E. van Muijen, L. S. van der Schoot, J. M. P. A. van den Reek, E. M. G. J. de Jong
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Pharmacology
Subjects:
psoriasis
dose reduction
dose tapering
clinical practice
implementation
biologics
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1505626/full
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1505626/full

Similar Items

  • Dose reduction of biologics in patients with plaque psoriasis: a review
    by: C. A. M. van Riel, et al.
    Published: (2024-03-01)
  • Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
    by: Selma Atalay, et al.
    Published: (2022-07-01)
  • Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
    by: L.S. van der Schoot, et al.
    Published: (2023-12-01)
  • Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study
    by: Lara S. van der Schoot, et al.
    Published: (2021-10-01)
  • Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
    by: Marloes E. van Muijen, et al.
    Published: (2022-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs